TG Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

TG Therapeutics (NASDAQ:TGTX) Third Quarter 2024 Results

Key Financial Results

• Revenue: US$83.9m (down 49% from 3Q 2023).
• Net income: US$3.88m (down 97% from 3Q 2023).
• Profit margin: 4.6% (down from 69% in 3Q 2023). The decrease in margin was primarily driven by higher expenses.
• EPS: US$0.027 (down from US$0.80 in 3Q 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

TG Therapeutics Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 2.7%. Earnings per share (EPS) missed analyst estimates by 28%.

Looking ahead, revenue is forecast to grow 35% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company's shares are down 5.3% from a week ago.

Balance Sheet Analysis

While it's very important to consider the profit and loss statement, you can also learn a lot about a company by looking at its balance sheet. We've done some analysis and you can see our take on TG Therapeutics' balance sheet.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.